SCHEMBL6917469

SCHEMBL6917469

O=C(O)CCNC(=O)c1ccc(C(=O)C(CC(=O)c2ccc(C3CCCCC3)cc2)c2cccc(Br)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 6/20 0.43
CYP2D6 P10635 1/20 0.43
GIPR P48546 1/20 0.43
HAO1 Q9UJM8 1/20 0.40
PGR P06401 1/20 0.40
AR P10275 1/20 0.40
APAF1 O14727 1/20 0.40
LMNA P02545 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
BCL2L1 Q07817 2/20 0.38
MCL1 Q07820 2/20 0.38
TAOK1 Q7L7X3 1/20 0.37
TAOK3 Q9H2K8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654247 0.92 LMNA (0.43) GCGRCYP2D6GIPRHAO1PGR
SCHEMBL2654474 0.89 HAO1 (0.42) GCGRCYP2D6HAO1APAF1KMT2A
SCHEMBL2653731 0.88 HAO1 (0.46) GCGRCYP2D6HAO1PGRAPAF1
SCHEMBL2647381 0.85 GCGR (0.48) GCGRCYP2D6GIPRHAO1BCL2L1
SCHEMBL2660182 0.85 GCGR (0.45) GCGRCYP2D6HAO1APAF1SMN1; SMN2
SCHEMBL2647568 0.85 GCGR (0.45) GCGRCYP2D6HAO1APAF1SMN1; SMN2
SCHEMBL2647125 0.84 CYP2D6 (0.45) GCGRCYP2D6HAO1APAF1LMNA
SCHEMBL2647801 0.82 GCGR (0.46) GCGRCYP2D6HAO1APAF1SMN1; SMN2
SCHEMBL6756859 0.82 GCGR (0.49) GCGRCYP2D6HAO1APAF1
SCHEMBL2646694 0.82 GCGR (0.49) GCGRCYP2D6HAO1APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR GCGR 4/4885CYP2D6 2704/4885GIPR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.